Target and Asset Review
The Challenge: TherapeutAix was approached by a small virtual biotech to review a target and asset that for a rare fibrotic disease. The company asked for specific help in reviewing the target, existing data, defining the steps then required to take the asset to IND and into the clinic. The task was to review the existing data and background information and to provide an […]
Translational Strategy
The Challenge: A small, highly virtualized biotech had identified an attractive target in fibrotic diseases and needed a translational strategy to generate clinical data that enables data-driven decision-making for future development as well as increases the asset value. The Action: TherapeutAix was contracted to define the translational approach scoping elements ranging from in vitro / in […]
Thoughts from the Extracellular Matrix Pharmacology Symposium
Last week the TherapeutAix team participated in the excellent Extracellular Matrix Pharmacology Symposium, hosted by our network partner Nordic Bioscience. This was a 2-day virtual event, with more than 500 scientists attending to share research and discuss all things extracellular matrix (ECM). Here on the blog, we are revisiting 3 points that got us thinking. Correlations with disease: Throughout the meeting, there was data demonstrating that differences in matrix […]
Inhaled Drug Delivery to the Lung
The Challenge: TherapeutAix was approached by a small biotech company developing a device with the potential to enhance inhaled drug delivery to the lung. The company required guidance on the choice of indication and drug to provide proof of principle (PoP) for the enhanced delivery. We were requested to scan the existing inhaled drug landscape and provide recommendations […]